The FDA is weighing the regulatory fate of KarXT — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. If approved, the fixed-dose combination of xanomeline and ...

An experimental new medication claims to help people lose weight without muscle loss. Here’s what you need to know about the ...

New psychoactive substances, originally developed as potential analgesics but abandoned due to adverse side effects, may ...

G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

Researchers created a tool capable of comprehensively mapping crucial interactions underlying drug efficacy in one superfamily of cell receptors. One in every three FDA-approved drugs targets a single ...

The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

Drugs that target opioid receptors sometimes have severe side effects. Thousands of people around the world die every day from overdoses involving opioids such as fentanyl. An international team of ...

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial.

Oct. 28 -- TUESDAY, Oct. 27 (HealthDay News) -- Some common herbicides and cholesterol drugs block a nutrient-sensing receptor known as T1R3, researchers report. "Compounds that either activate or ...

For years, people taking one of the world’s most common heart drugs have described the same nagging side effect: sore, aching ...